Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model

Thrombosis Research

Volumn 89, Issue 3, 1998, Pages 129-136

  Aoki, Toshiaki ^a   Cox, Dermot ^a   Senzaki, Kayoko ^a   Seki, Jiro ^a   Tanaka, Akito ^a   Takasugi, Hisashi ^a   Motoyama, Yukio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Aspirin; FK633; GPIIb IIIa antagonist; Platelet; Thrombolysis; Thrombosis

Indexed keywords

4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; N2 [N2 4 (4 AMIDINOPHENOXY)BUTYRYL] ALPHA ASPARTYL VALINE MONOHYDRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ASPIRIN; CAROTID ARTERY THROMBOSIS; DIPEPTIDES; FIBRINOLYTIC AGENTS; GUINEA PIGS; INJECTIONS, INTRAVENOUS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032004586     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00308-3     Document Type: Article

References (30)

1. 1. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
2. 2. Rubenstein MD, Wall RT, Bain DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981; 102:363-7.
3. 3. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985;53:363-73.
4. 4. Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986;315:1023.
5. 5. Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986;8:245.
6. 6. Stein BS, Fuster V, Israel DM, Cohen M, Badimon L, Badimon J, Chesebro JH. Platelet inhibitor agents in cardiovascular disease: An update. J Amer Coll Cardiol 1989;14(4): 813-36.
7. 7. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
8. 8. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 1989;10:453-8.
9. 9. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of RGD specific adhesion receptors. Science 1986;231: 1559-62.
10. 10. Nachman RL, Leung LLK. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69:263-9.
11. 11. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIb/IIIa antagonist. Drugs Fut 1994;19(2):135-59.
12. 12. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985;82:8057-61.
13. 13. Bhattacharya S, Machin SJ, Lahiri A. Therapeutic implications of a specific murine monoclonal antibody (7E3) to the platelet receptor GPIIb/IIIa. Platelets 1992;3:119.
14. 14. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
15. 15. Simoons ML, Van Der Brand M, Hoorntje JCA, et al. Chimeric 7E3 antiplatelet antibody Fab for the treatment of refractory unstable angina: A placebo-controlled pilot study. J Am Coll Cardiol 1992;21:269A.
16. 16. Aoki T, Cox D, Senzaki K, Seki J, Tanaka A, Takasugi H, Motoyama Y. The anti-platelet and anti-thrombotic effects of FK633, a peptide mimetic GPIIb/IIIa antagonist. Thromb Res 1996;81:439-50.
17. 17. Kurz KD, Main BW, Sandusky GE. Rat model of thrombosis induced by ferric chloride. Thromb Res 1990;60:269-80.
18. 18. Smith GF, Neubauer BL, Sundboom JL, et al. Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat thrombosis. Thromb Res 1988;50:163-74.
19. 19. Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamidine: A non-peptide GPIIb/IIIa antagonist - In vitro studies on platelets from humans and other species. Thromb Haemostas 1992;68:731-6.
20. 20. Harfenist EJ, Packham MA, Musterd JF. Effect of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. Blood 1988;71:132-6.
21. 21. Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nicholas AJ, Ohlstein EH. Antithrombotic effects of platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke 1992;23:703-11.
22. 22. Kaku S, Kawasaki T, Hisamichi N, Sakai Y, Taniuchi Y, Inagaki O, Yano S, Suzuki K, Terazaki C, Masuho Y, Satoh N, Takenaka T, Yanagi K, Ohshima N. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkey. Thromb Haemostas 1996; 75:679-84.
23. 2 in reocclusion after thrombolysis. Thromb Haemostas 1995;73: 683-8.
24. 24. The SALT Collaboration Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;328:1345-9.
25. 25. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment. Part 1: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;38:81-106.
26. 26. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-82.
27. 27. Haley EC Jr, Brott TG, Sheppard GL, Barsan W, Broderick J, Marier JR, Kongable GL, Spilker J, Massey S, Hansen CA, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24: 1000-4.
28. 28. Overgaard K, Sperling B, Boysen G, Pedersen H, Gam J, Ellemann K, Karle A, Arlien-Soborg P, Olsen TS, Videbaeck C, et al. Thrombolytic therapy in acute ischemic stroke. Stroke 1993;24:1439-46.
29. 29. EPIC Investigators. Use of a monoclonal antibody direct against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-61.
30. 30. The EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-90.